Novo Nordisk A/S (NVO) — Technical Analysis Weekly (1W) | Current price: ~$47.51
Market Structure
NVO remains in a long-term bearish trend, clearly defined by the descending orange trendline from the ~$78 area.
However, the current price action is becoming interesting because NVO is approaching a potential accumulation/reversal zone around $45–47.
🟢 LONG SETUP
Entry Zone: $45–47
This is the zone marked on the chart, and technically it makes sense because price is:
Testing the descending trendline.
Holding above the major $40.74 support.
Showing repeated attempts to stabilize around $45–47.
Stop Loss: $40
A weekly breakdown below ~$40 would invalidate the current bullish reversal thesis.
🎯 Upside Targets
T1: $58.74–59.52
First major resistance and the most important target. This area combines horizontal resistance with the previous breakdown zone.
T2: $78.14–79.58
Major resistance and the upper target shown on the chart.
Potential path:
$45–47 → $50 → $58.7–59.5 → $61.89 → $78–79.6
🔥 The Key Technical Event
The most important thing I would watch is a weekly breakout above the orange descending trendline.
If NVO closes decisively above the trendline and then successfully retests it as support, that would be a significant trend-reversal confirmation.
In that case, the probability of reaching $58.7–61.9 increases substantially.
A clean breakout through $61.89 would make the larger $78–80 target much more realistic.
🔴 Bearish Scenario
If price fails at the trendline and loses $45, the stock could retest:
$40.74 → $38 → $35
A weekly close below $40.74 would be a major warning, while your $40 stop provides a clear invalidation level.
📈 Risk/Reward
Using an average entry of $46:
Risk to $40 = ~$6
T1 midpoint ≈ $59.1 → ~2.2R
T2 midpoint ≈ $78.9 → ~5.5R
So the setup has a very attractive asymmetric R/R, but the key issue is that NVO is still technically inside the long-term downtrend.
🧠 TradingView Verdict
NVO is a high-risk/high-reward reversal setup rather than a confirmed uptrend. The $45–47 zone is attractive for staged accumulation, with $40 as the structural invalidation. The first major confirmation comes from a weekly breakout above the descending trendline, followed by $58.74–59.52. A breakout above $61.89 would dramatically strengthen the bullish case toward $78–80.
Bias: 🟡 Speculative Bullish above $45 | 🟢 Strong Bullish above $60 | 🔴 Bearish below $40
In-depth trading ideas
NVO | Weekly Structure | $48 Could Unlock the Bull CaseThesis:
NVO has spent more than a month compressing inside my $44-$48 accumulation zone, around several important long-term technical levels. I believe this consolidation is becoming increasingly constructive. If $48 can break and then flip to support, I would consider the Bull Case active and expect the next impulsive move higher to begin.
Context
- Weekly timeframe
- This is an update to my long-term NVO cycle analysis published earlier this year
- Price has been oscillating around the $44-$48 area since the end of July
- The range sits around the recent breakout structure and several important moving averages
- Q2 adjusted sales grew 7% at constant exchange rates
- Adjusted operating profit grew 11% at constant exchange rates
- Management also raised its 2026 adjusted sales and operating profit outlook
- The Wegovy pill has now started its European rollout
- NVO remains one of my largest long-term portfolio positions
What I see
- The larger ABC correction appears complete
- Price has been building a tight range directly above the lower boundary of my long-term structure
- Bulls and bears have clearly defined the current battleground between approximately $44 and $48
- Weekly momentum has recovered materially from the oversold conditions seen during the correction
- The price action increasingly looks like compression rather than another impulsive move lower
- $48 remains the first level that needs to be reclaimed before I become more aggressive on the Bull Case
What matters now
- $44 remains the lower boundary of the current accumulation area
- $48 is the key breakout level
- I want to see price break above $48 and then prove that former resistance can become support
- If that happens, I expect momentum to accelerate and the next leg of the larger cycle to begin
- The first major technical area above sits around $70
- The 200-week MA currently sits around the low-$80s and would become the next major structural test
Buy / Accumulation zone
- My accumulation zone remains approximately $44-$48
- I added again inside this range around $46
- My current portfolio average is approximately $47.70
- I remain comfortable building the position while price stays inside this long-term accumulation structure
- I have no interest in chasing a breakout before support is confirmed
Targets
- Bull Case trigger: breakout and hold above $48
- Initial Wave 3 area: approximately $70
- Major structural resistance: 200-week MA around $80-$82
- Higher-degree Wave 3 target: approximately $240
- 1.618 Fibonacci extension: approximately $240.60
Portfolio note
NVO is not a short-term position for me.
I am looking at this chart through a much larger Elliott Wave and Fibonacci cycle, with a holding horizon that can extend seven to ten years if the fundamental thesis continues to develop.
The current higher-degree Wave 3 target around $240 is therefore not a short-term forecast. It is the main technical reference for the larger cycle I am tracking.
Beyond that, the full super-cycle could eventually open the door to a Wave 5 significantly higher, potentially around the $360 area based on the structure visible today. That is several years away and far too early to treat as an active target, but it explains why I am willing to remain patient with the position.
For now, the chart is much simpler.
Hold the accumulation structure, reclaim $48, and then let the next wave prove itself.
Novo Nordisk A/S Class B (NOVO_B) – Bearish Setup | Target: 287Novo Nordisk A/S Class B (NOVO_B): Arc Cycle Analysis
Overview: Based on Arc Cycle Analysis applied to the 2h chart, Novo Nordisk is interacting with the 0.786 Arc within the current Arc Cycle. Price remains centered around this Arc, indicating that directional confirmation has not yet been established.
Novo Nordisk – Bullish Setup | Target: 306.00 #44NOVO_B Price Outlook: Novo Nordisk Holds Above 1 (100%) Support Arc | Potential Rebound Toward 306.00
Novo Nordisk A/S Class B (NOVO_B): Arc Cycle Analysis
Overview: Based on Arc Cycle Analysis applied to the 30m chart, Novo Nordisk is interacting with the 1 (100%) Support Arc within the current Arc Cycle. Price is holding above this Support Arc, suggesting the potential for a bullish rebound toward the next Resistance Arc.
Market Outlook
Price is holding above the 1 (100%) Support Arc, indicating that this Arc continues to provide support within the current Arc Cycle. If the Support Arc continues to hold, a rebound toward 306.00 price becomes the preferred scenario.
Conversely, a sustained 30m close below the Support Arc at 294.00 would invalidate the bullish scenario and shift the outlook toward the next lower Support Arc.
EW count suggests that Novo might be reversingMy count is disproportionate and wave 3 in (3) is not the smallest only on log scale. However, there are chances that the stock has reversed its trend.
Zigzag correction off the top might be done and I outlined a couple of leading diagonal scenarios that might play out.
What I really like is wave (C) sharp movement which raises chances that we've bottomed.
Alternative option is that the bottom to be seen later if $35 breaks.
I'd say that the stock needs to find support above $51 during this year and we have good chances to prosper.
$NVO , IdeaWeekly chart. A pharma giant at a crossroads.
NVO lost over 70% from its 2024 peak. The GLP-1 narrative cracked, competition arrived, and the market repriced brutally. Now at $43, it sits just above two major demand zones.
Two scenarios on the table:
Scenario 1 (yellow) : Capitulation into the $22 zone, a bounce back toward $48–$52 resistance, then rejection and a final flush into the deeper $10.50–$12.50 zone. The full reset. Classic distribution-to-markdown sequence.
Scenario 2 (cyan) : The trap. A drop into $22 first, followed by a genuine recovery that reclaims $48–$52 and launches toward $100+. The people who sold the bottom fund the next bull run.
The $22 zone is the fulcrum. How price behaves there tells the story.
This is not a trade call. This is structure reading on a name that went from darling to wreckage in 12 months. The system watches. The zones are marked.
When the signal comes, the rules decide.
Follow, Boost, Thank You!
⚠️ Financial Disclaimer: This post is not financial advice. I am not your financial advisor, your life coach, or your legally responsible adult. Always do your own research and never trade based solely on internet comedy.
NVO: Bullish Pennant Breakout Unlocks $+70$ Macro Target### **The Macro Picture**
Following a strong rally into early **2026**, **Novo Nordisk A/S ( NYSE:NVO $)** entered a healthy, multi-month consolidation phase. During this time, the price formed a textbook **Bullish Pennant** pattern, systematically carving out a series of lower highs and higher lows.
The compression phase has officially resolved to the upside. With price currently trading at **$50.56**, NYSE:NVO $ has cleanly broken out of the descending resistance trendline and is showing strong signs of a structured, healthy uptrend.
---
### **Key Technical Parameters**
Our automated pattern detector has mapped out a highly precise structural setup with a clean **1:4 Risk-to-Reward ratio**:
* **Entry Trigger Zone:** **$43.94** *(Clean breakout and retest of the upper pennant boundary)*.
* **Current Price:** **$50.56** (showing solid momentum above the pivot).
* **Stop Loss (Invalidation):** **$36.99** *(Set just below the lower support boundary of the pennant structure)*.
* **Macro Target:** **$71.74** *(Measuring the length of the prior bullish pole applied to the breakout point)*.
---
### **Supporting Indicators & Fundamental Tailwinds**
* **Adaptive RSI Supertrend:** The momentum oscillator at the bottom of the daily chart shows a clean, upward curvature out of oversold territory. It confirms rising buying pressure without being overbought.
* **Regime Score:** Currently sitting at a maximum **100 / 100**, confirming strong high-timeframe (HTF) bullish alignment.
* **Fundamental Catalyst:** Underlying the technical breakout is a renewed surge in investor confidence. NYSE:NVO $’s semaglutide franchise (Wegovy and Ozempic) continues to secure key label expansions. Most notably, the brand-new oral Wegovy weight-loss pill launched on January 5, 2026, has already crossed a monumental milestone of over 3 million prescriptions in the U.S. alone, fueling upgraded commercial expectations for the year.
---
### **Trade Outlook**
The path of least resistance is firmly skewed to the upside. As long as the bulls maintain structure above the major **$44.00** breakout pivot, we expect this macro trend to continue marching toward our ultimate pattern target at **$71.74**.
Let me know what you think in the comments below! If you find this analysis helpful, please drop a like and follow for more clean setups.
**#TaxpayerTrades**
---
### **Disclaimer**
*This analysis is for educational and informational purposes only and should not be construed as financial, investment, or trading advice. Trading equities, options, and derivatives involves a high degree of risk and can result in the loss of principal. Please conduct your own due diligence or consult a licensed financial advisor before making any investment decisions. Past performance is not indicative of future results.*
Novo Nordisk (NVO) | 1D Technical AnalysisNovo Nordisk is approaching a critical technical inflection point after spending months in a primary downtrend. The recent price action is forming a Falling Wedge directly beneath the long-term descending trendline—a pattern that often precedes a bullish reversal when confirmed by a breakout.
Market Structure
The long-term trend remains bearish, defined by a sequence of lower highs and lower lows. However, the selling pressure has weakened significantly, and buyers are gradually regaining control.
Price is now testing two major technical barriers simultaneously:
The multi-month descending trendline
The upper boundary of the falling wedge
This confluence creates a high-probability decision zone.
Bullish Scenario
A daily close above the wedge resistance and the long-term trendline, ideally with above-average volume, would confirm a trend reversal.
Such a breakout could trigger:
Short-covering momentum
Fresh institutional buying
A transition from a bearish trend into a medium-term bullish structure.
Bullish Targets
Target 1: $54.00
Target 2: $58.00
Target 3: $62.00
Extended Target: $66.00–68.00
Bearish Scenario
Failure to break the descending trendline would keep the primary downtrend intact.
A rejection from current levels could lead to another decline toward:
$48.00
$46.00
$44.00 (major demand zone)
A daily close below the wedge support would invalidate the bullish setup.
Volume Analysis
Volume has contracted during the wedge formation, which is characteristic of a mature falling wedge.
The ideal confirmation would be:
Strong bullish candle
Volume expansion above the 20-day average
Breakout sustained by consecutive higher closes
Without volume confirmation, any breakout should be treated cautiously.
Momentum Outlook
The recent higher lows suggest improving momentum despite the broader bearish trend.
If buyers can establish a higher high above the recent swing high, the market structure would officially shift toward bullish.
Trading Plan
Buy Trigger
Daily close above the falling wedge resistance and long-term trendline.
Stop Loss
Below the recent swing low / wedge support.
Profit Targets
TP1: $54
TP2: $58
TP3: $62
Risk Assessment
Current Trend: Bearish
Short-Term Momentum: Improving
Pattern: Falling Wedge (Bullish Reversal)
Breakout Probability: 70–75% if confirmed with strong volume.
Risk/Reward: Approximately 1:3 after a confirmed breakout.
TradingView Summary
NVO is trading at a key technical decision point where a multi-month descending trendline converges with a bullish falling wedge pattern. Price compression and declining volume suggest the corrective phase may be nearing completion. A confirmed daily breakout above both resistance levels could mark the beginning of a medium-term trend reversal, opening the door toward $54, $58, and potentially $62. Until the breakout is confirmed, traders should remain patient and wait for volume-backed confirmation rather than anticipating the move.
Novo Nordisk (NOV)Novo Nordisk (NVO) reported strong first-quarter earnings on May 6, 2026, with sales jumping 32% to reach 96.8 billion Danish kroner (~$15.2 billion).
Driven by soaring demand for its popular GLP-1 weight-loss and diabetes drugs like Wegovy and Ozempic, the company beat earnings estimates and raised its full-year 2026 guidance.
Earnings Per Share (EPS): Novo reported a diluted Q1 EPS of $1.04, beating the average analyst estimates of $0.87.
The company raised its full-year guidance, projecting adjusted sales and operating profit growth of between -4% and -12% at constant exchange rates.
The company's next earnings report, covering the second quarter, is scheduled for release on August 5, 2026.
NVO: Bullish Pennant Signals Potential Return to $150Novo Nordisk appears to be developing a compelling long-term reversal setup after a prolonged decline from its previous highs.
Following a significant selloff, price has spent several months building a base between $38 and $50. The recent recovery has pushed NVO back above a key psychological level while a bullish pennant pattern continues to develop on the weekly timeframe.
The current structure suggests accumulation may be transitioning into a new uptrend. A sustained move above the $50 area could open the door to higher resistance levels near $60, $80, and eventually $100.
If bullish momentum continues and the pattern completes, the longer-term measured move projects toward the $150 region.
Key Levels:
• Support Zone: $38 - $43
• Current Price: $50.43
• Entry Trigger: $49.96
• Resistance: $60, $80, $100
• Long-Term Target: $150
The bullish outlook remains valid while price continues holding above the major accumulation zone.
Not financial advice.
NVO: Weekly Falling Wedge Lines Up With Key FVGNovo Nordisk (NVO) is basing after an extreme drawdown — the stock ran from ~$40 to ~$150 through 2024, then gave nearly all of it back in a sharp decline back to the low $40s on GLP-1 competition and trial-data pressure.
Price just printed an +11.30% weekly reversal candle, closing at 48.07, and the pattern detector has flagged the recovery structure off the bottom as a Bullish Pennant.
Setup — Weekly Bullish Pennant
Entry: 49.96
Stop: 24.83
Target: 150.49
Risk:Reward: ~4R
R:R Quality: 80% | Pivot Depth: 100% | 26 bars since the pennant break
Price is sitting just under the 49.96 trigger after this week's reversal candle — not yet confirmed above the entry line.
Momentum
The custom ML RSI is climbing out of the high-30s/low-40s zone with a rising trendline under the recent lows, supporting the base-building thesis alongside price.
Invalidation
A weekly close back below the 24.83 stop invalidates the pennant thesis and would suggest the downtrend is resuming rather than basing.
Bias
Bullish above 49.96 confirmation, targeting a measured move back toward 150.49. This is a multi-month, high R:R swing setup — not a quick trade.
This is technical analysis for educational purposes, not financial advice. Do your own research and manage risk accordingly.
Downtrend Breakout Reversal.Novo Nordisk (NVO) currently represents a high-quality large-cap growth franchise in a transitional market phase, where fundamentals and technicals are beginning to realign after a significant sentiment-driven drawdown. The company remains structurally advantaged with dominant positioning in the GLP‑1 obesity and diabetes markets, strong double-digit revenue growth (~30%+), high margins, and robust cash generation, yet trades at a compressed valuation (~11x earnings), reflecting market concerns around competition from Eli Lilly, growth normalization, and pipeline uncertainty; this creates a credible variant perception opportunity where expectations may be overly pessimistic relative to long-term demand dynamics.
Technically, the stock is attempting to exit a prolonged downtrend and is now testing a critical $48–50 resistance zone, with a confirmed breakout likely catalyzing a shift toward an intermediate uptrend targeting $60+, while downside remains contained near $40–45 support.
$NVO (Novo Nordisk): 1-day. CUP & HANDLE breakout!NYSE:NVO (Novo Nordisk): 1-day
Six days later, and in my opinion it's still the best-looking chart among the large-cap names.
The price has reclaimed the green 200 MA ($47.8), which should now act as the main support zone if a pullback develops. I still think we're in Elliott Wave 3, so I'd consider a correction somewhere between $42.5 and $46.
The yellow 50 MA is sitting at $44.5 and could catch up to the 200 MA from below within the next few days, potentially forming a Golden Cross. Daily RSI is approaching 90, so the market is becoming overbought and a pullback is likely. Keep in mind that this entire impulse started below $40, so I don't expect an immediate move to the Cup & Handle breakout target around $60. A correction beforehand seems more likely.
Fundamentally, Q1 results were strong. The next earnings report is scheduled for August 5, and the most important thing to watch will be sales of its key drugs. But for me, the chart remains the most important part of the story - it looks like a breakout from a long accumulation phase following the correction that began after the all-time high just below $150 in June 2024.
💙👽
We're now on the verge of breaking above the channel.NYSE:NVO is now back above $50.
Bought the exact bottom and still fully long.
We're now on the verge of breaking above the channel. I think the higher-probability scenario is that we've transitioned into a trading range (yellow).
If that's the case, we're now around the middle of that range, making the $60 area the first upside target.
#NovoNordisk NYSE:LLY #Stocks
NVO: Massive Weekly Bullish Pennant Nearing Macro Breakout📊 Macro Overview & Structural Context
Looking at the NVO weekly chart, price action is currently compressing inside a massive, long-term Bullish Pennant pattern that has been forming since mid-2024. Following a powerful multi-year impulse wave, this extended correction has allowed the stock to fully reset its technical indicators and mitigate deep structural liquidity pools.
🔍 Key Technical Observations
SMC Demand Mitigation: The FluidTrades SMC indicator reveals that price is actively reacting out of a major macro Demand Zone / Order Block located between the $40 – $48 region.
Liquidity Sweeps: Recent lower timeframe wick action indicates a sweep of internal sell-side liquidity, followed by solid structural absorption from macro buyers defending this key structural floor.
The Reversal Apex: Price is reaching the absolute apex of the converging trendlines. A definitive breakout line sits near $49.96, which would mark a clean weekly Change of Character (CHoCH) to confirm the macro correction is complete.
🎯 Long-Term Target Projection
Entry Trigger: A clean daily or weekly candle close above $49.96.
Invalidation / Stop Loss: A macro breakdown below structural demand at $24.83.
Ultimate Target: $150.49 (Representing a projected measured move of the pennant structure if institutional momentum completely returns).
⚠️ Disclaimer: This analysis is based strictly on algorithmic structural models for educational purposes and does not constitute financial advice. Always manage your position sizing according to your personal risk tolerances.
Is Novo breaking out of a falling trend channel?In 2024, Novo formed a head–shoulder pattern with a breakdown at the end of September. Since then, the stock has been moving within a falling trend channel until now.
On September 18 this year, the stock broke above the trend channel by 6–7% on increased volume. It has since pulled back to test the upper line of the channel and is now moving up again.
There is resistance around 390. If the stock breaks significantly above this level with rising volume, it will be clearly technically positive.
Price momentum indicators are currently neutral, and the stock remains within a red Ichimoku cloud, but RSI 21 is trending higher.
The stock is slightly technically positive at this point but could quickly turn decisively positive if it breaks above 390.
The analysis covers a medium-term horizon (1–6 months).
Fundamentals:
Fundamental analysts remain broadly positive on the stock.
“Novo announced a global restructuring affecting 9,000 employees.
The purpose is to increase decision-making speed, strengthen performance culture, and redirect resources toward growth areas within diabetes and obesity ...
Despite short-term uncertainty, we assess that growth potential remains attractive (though somewhat lower than previously expected). The pipeline is strong, and Novo remains in a leading capacity position.”
Quoted from Jyske Bank, Denmark.
Disclaimer:
I hold a position in the stock.
Note: You must do your own research and assessment before buying or selling shares.
$NVO (Novo Nordisk) - 1-day, BREAKOUT from ACCUMULATION?NYSE:NVO (Novo Nordisk) - 1-day
One of the cleaner charts out there. The stock has been correcting since its 2024 all-time high ($148), and since 2025 we've started to see signs that the selling pressure is slowing down.
There was a weak breakout from the Falling Wedge (measured move target around $91+), and now a nice Cup & Handle pattern appears to be forming. The neckline sits around $47, with the 200-day moving average (green) at approximately $48.
If this really is a valid Cup & Handle, the classical technical target comes in just under $60.
An interesting chart to keep on the watchlist. This is not a signal or financial advice.
👽💙
Why $NVO's Weekly Close Just Triggered a Buy SignalHere is a complete, structured draft for your TradingView idea post using that title. It blends the strong weekly technical setup shown on your chart with the recent fundamental catalysts (like the UK oral Wegovy approval and the solid bounce off the March lows) to give your readers a comprehensive breakdown.
---
# 🔍 Eye on NVO: Key Support Holds for a Massive Weekly Rebound
## 📊 The Macro Setup (Weekly Chart)
After enduring a brutal correction earlier this year that bottomed out in late March near the **$35–$36 demand zone**, Novo Nordisk ( NYSE:NVO ) has spent the last few months quietly building a massive structural base.
This week’s price action confirms that the bulls have officially taken back control of the higher-timeframe trend. The weekly close is triggering a major technical buy signal for several key reasons:
* **Key Support Validation:** The stock successfully retested and held its critical macro demand shelf. Selling pressure has completely exhausted, leading to a strong, high-volume rejection of lower prices.
* **Moving Average Reclaiming:** NVO has surged back above its short-term exponential moving averages (EMAs) on the weekly timeframe, turning previous structural resistance back into a support floor.
* **Momentum Shift:** The Weekly Relative Strength Index (RSI) is curling sharply upwards out of neutral territory, indicating that buying momentum is accelerating with real conviction.
---
## 💡 Fundamental Tailwinds
The technical breakout is being fueled by a powerful shift in market sentiment and recent commercial updates:
* **Regulatory Catalysts:** Sentiment has been strongly boosted by the recent **UK approval of the oral Wegovy pill**, making it the first European nation to clear the daily weight-loss tablet.
* **Robust Adoption:** In the U.S., oral Wegovy prescriptions recently topped 3 million within just over five months of launch, proving that international volume expansion is successfully offsetting domestic pricing pressures.
* **Strong Pipeline Data:** Positive Phase 3 REIMAGINE data for *CagriSema* presented at the ADA conference has reinforced long-term confidence in NVO's competitive edge in the obesity and diabetes space.
---
## 🎯 Key Levels to Watch
### 🟢 Long Entry / Support Zones
* **Primary Support ($44.00 – $45.00):** This is the immediate accumulation zone. As long as NVO holds above this reclaimed structural shelf on a weekly closing basis, the macro trend remains firmly bullish.
* **Invalidation / Stop Loss:** A sustained weekly close below the **$41.00** level would invalidate this specific rebound setup.
### 🔴 Upside Targets
1. **Target 1 ($48.50 – $50.00):** Immediate overhead resistance and psychological barrier. Clearing the $50 mark opens the floodgates.
2. **Target 2 ($54.00):** Major liquidity gap and structural resistance from earlier in the year.
3. **Target 3 ($58.00+):** Longer-term macro target if the recovery sustains ahead of the Q2 earnings report in August.
---
⚠️ Risk Disclaimer: This post is for educational and informational purposes only and does not constitute financial advice. Always manage your risk and position size according to your personal trading plan.
What are your thoughts on NVO here? Are you buying the weekly breakout, or waiting for a deeper retest? Let me know in the comments below! 👇
NVO: Mapping the Symmetrical Triangle Breakout We’ve been sitting in this range, grinding through a consolidation phase for months, but the coiled spring looks like it's finally snapping. Novo just cleared the upper trendline of its symmetrical triangle on a strong daily close at $47.42 (Jun 23, 2026) backed by an acceleration in volume to 17.87M.
This compression has been building ever since we washed out at the year-to-date low of $35.12. Since then, it’s been a steady accumulation process marked by a clean series of higher lows. The stock, IMO, is long overdue to realize some significant upside, and this structural breakout confirms the bulls are finally reclaiming control.
The Upside Roadmap:
I'm mapping out two distinct horizontal resistance levels as my price targets from here:
R-1 ($50.54): The immediate overhead shelf and former breakdown zone. Clearing and converting this level changes the entire medium-term complex.
R-2 ($62.24): The major structural supply layer from earlier this year. That is the ultimate target for this run.
How I’m Positioned:
I’ve been long on this name since the mid-30s. To maximize the long setup, I'm running a three-tier execution:
Common Stock: Holding the core long position established at the base... and accumulating.
LEAPs: Aggressively capturing delta expansion as volatility expands out of this triangle pattern.
Selling Puts: Been capitalizing on the defined structural floor by writing puts to continuously pocket premium and lower my net basis.
As always, this represents my personal thoughts and trading thesis. This is not investment advice... do your own due diligence and manage your own risk. Giddy up!
NVO : Novo Nordisk - End of bearish pressure ?Some good news supported NVO's price last 8 weeks.
And it keeps going higher after its majority owner announced a new push into obesity and metabolic disease research.
A big major breakout ( Closing above 50$ s) may send the stock's price 62$, 78$ and 90$.
Added to watchlist.
NVO has bottomed BUT not an immediate BuyNvo has been under a lot of discussion for it falls under the classic value stock category, but unfortunately in the market rewarding growth over Value.
From Technical charts (on weekly/monthly), there are strong indications that 36$ was its long time bottom but daily charts are projecting fall back to a double bottom levels in the 35-38$ time frame.
From investment PoV, would rather put this stock on the watchlist and look back again in July-Aug then buying it right now.
$NVO The obesity drug market is still in its early innings.NYSE:NVO , CVS is making GLP-1 drugs easier to access with $49 virtual visits and prescription support.
More access = more potential patients.
The obesity drug market is still in its early innings.
Not holding many longs right now, but Novo Nordisk is one of them.
NYSE:CVS NYSE:NVO NYSE:LLY #GLP1 #Obesity #Stocks #Investing






















